Dendritic cells for active anti-cancer immunotherapy: Targeting activation pathways through genetic modification

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 9, Issue 4, 2009, Pages 328-343

  Breckpot, Karine ^a,b   Escors, David ^b  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cancer; Cytotoxic T lymphocytes; Dendritic cell; Gene therapy; Toll like receptor; Transcription factor

Indexed keywords

ALPHA INTERFERON; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; VIRUS VECTOR;

ADAPTIVE IMMUNITY; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CELL MATURATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EFFECTOR CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; IMMUNE SYSTEM; NONVIRAL GENE DELIVERY SYSTEM; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTIGENS, NEOPLASM; AUTOANTIGENS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; GENE THERAPY; HUMANS; IMMUNOTHERAPY, ACTIVE; INTERLEUKINS; MICE; NEOPLASMS;

EID: 75749136925     PISSN: 18715303     EISSN: None     Source Type: Journal    
DOI: 10.2174/187153009789839156     Document Type: Review

References (212)

1. Shaw, G.B. (2003) The Doctor's Dilemma. Int. J. Epidemiol., 32, 910-915.
2. Ehrlich, P. (1909) Ueber den jetzigen Stand der Karzinomforschung. Ned. Tijdschr. Geneesk, 5, 273-290.
3. Mak, T.W. (2007) The T cell antigen receptor: "The Hunting of the Snark". Eur. J. Immunol., 37, S83-S93.
4. Burnet, F.M. (1970) The concept of immunological surveillance. Prog. Exp. Tumor Res., 13, 1-27.
5. Boon, T. and van der Bruggen, P. (1996) Human tumor antigens recognized by T. lymphocytes. J. Exp. Med., 183, 725-729.
6. Van den Eynde, B.J. and van der Bruggen, P. (1997) T cell defined tumor antigens. Curr. Opin. Immunol., 9, 684-693.
7. Pittet, M.J. and Mempel, T.R. (2008) Regulation of T-cell migration and effector functions: insights from in vivo imaging studies. Immunol. Rev., 221, 107-129.
8. Lurquin, C.; Lethe, B.; De Plaen, E.; Corbiere, V.; Theate, I.; van Baren, N.; Coulie, P.G. and Boon, T. (2005) Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J. Exp. Med., 201, 249-257.
9. Gattinoni, L.; Powell, D.J. Jr.; Rosenberg, S.A. and Restifo, N.P. (2006) Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol., 6, 383-393.
10. Tuyaerts, S.; Aerts, J.L.; Corthals, J.; Neyns, B.; Heirman, C.; Breckpot, K.; Thielemans, K. and Bonehill. A. (2007) Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol. Immunother., 56, 1513-1537.
11. Steinman, R.M. and Cohn, Z.A. (1973) Identification of a novel cell type in peripheral lymphoid organs of mice. I: morphology, quantitation, tissue distribution. J. Exp. Med., 137, 1142-1162.
12. Young, J.W. and Steinman, R.M. (1996) The hematopoietic development of dendritic cells: a distinct pathway for myeloid differentiation. Stem Cells, 14, 376-387.
13. Steinman, R.M. (2003) Some interfaces of dendritic cell biology. APMIS, 111, 675-697.
14. Breckpot, K.; Heirman, C.; Neyns, B. and Thielemans, K. (2004) Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells. J. Gene Med., 6, 1175-1188.
15. Steinman, R.M. (2007) Dendritic cells: understanding immunogenicity. Eur. J. Immunol., 37, S53-S60.
16. Ueno, H.; Klechevsky, E.; Morita, R.; Aspord, C.; Cao, T.; Matsui, T.; Di Pucchio, T.; Connolly, J.; Fay, J.W.; Pascual, V.; Palucka, A.K. and Banchereau, J. (2007). Dendritic cell subsets in health and disease. Immunol. Rev., 219, 118-142.
17. O'Keeffe, M.; Hochrein, H.; Vremec, D.; Caminschi, I.; Miller, J.L.; Anders, E.M.; Wu, L.; Lahoud, M.H.; Henri, S.; Scott, B.; Hertzog, P.; Tatarczuch, L. and Shortman, K. (2002) Mouse plasmacytoid cells: long-lived cells, heterogeneous in surface phenotype and function, that differentiate into CD8(+) dendritic cells only after microbial stimulus. J. Exp. Med., 196, 1307-1319.
18. Fitzgerald-Bocarsly, P.; Dai, J. and Singh, S. (2008) Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor Rev., 19, 3-19.
19. Dzionek, A.; Sohma, Y.; Nagafune, J.; Cella, M.; Colonna, M.; Facchetti, F.; Gunther, G.; Johnston, I.; Lanzavecchia, A.; Nagasaka, T.; Okada, T.; Vermi, W.; Winkels, G.; Yamamoto, T.; Zysk, M.; Yamaguchi, Y. and Schmitz, J. (2001) BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J. Exp. Med., 194, 1823-1834.
20. Grouard, G.; Rissoan, M.C.; Filgueira, L.; Durand, I.; Banchereau, J. and Liu, Y.J. (1997). The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J. Exp. Med., 185, 1101-1111.
21. Bauer, M.; Redecke, V.; Ellwart, J.W.; Scherer, B.; Kremer, J.P.; Wagner, H. and Lipford, G.B. (2001) Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells. J. Immunol., 166, 5000-5007.
22. Gilliet, M.; Boonstra, A.; Paturel, C.; Antonenko, S.; Xu, X.L.; Trinchieri, G.; O'Garra, A. and Liu, Y.J. (2002) The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocyte/macrophage colonystimulating factor. J. Exp. Med., 195, 953-958.
23. Robinson, S.P.; Patterson, S.; English, N.; Davies, D.; Knight, S.C. and Reid, C.D. (1999) Human peripheral blood contains two distinct lineages of dendritic cells. Eur. J. Immunol., 29, 2769-2778.
24. van Duin, D.; Medzhitov, R. and Shaw, A.C. (2006) Triggering TLR signaling in vaccination. Trends Immunol., 27, 49-55.
25. Krug, A.; Towarowski, A.; Britsch, S.; Rothenfusser, S.; Hornung, V.; Bals, R.; Giese, T.; Engelmann, H.; Endres, S.; Krieg, A.M. and Hartmann, G. (2001) Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur. J. Immunol., 31, 3026-3037.
26. Michiels, A.; Breckpot, K.; Corthals, J.; Tuyaerts, S.; Bonehill, A.; Heirman, C.; Thielemans, K. and Aerts, J. L. (2006) Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells coelectroporated with a dsRNA analogue and tumor antigen mRNA. Gene Ther., 13, 1027-1036.
27. Breckpot, K.; Corthals, J.; Bonehill, A.; Michiels, A.; Tuyaerts, S.; Aerts, C.; Heirman, C. and Thielemans, K. (2005) Dendritic cells differentiated in the presence of IFN-{beta} and IL-3 are potent inducers of an antigen-specific CD8+ T cell response. J. Leukoc. Biol., 78, 898-908.
28. Jonuleit, H.; Schmitt, E.; Steinbrink, K. and Enk, A.H. (2001) Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol., 22, 394-400.
29. Mahnke, K.; Schmitt, E.; Bonifaz, L.; Enk, A.H. and Jonuleit, H. (2002) Immature, but not inactive: the tolerogenic function of immature dendritic cells. Immunol. Cell Biol., 80, 477-483.
30. Martin, P.; Del Hoyo, G.M.; Anjuere, F.; Arias, C.F.; Vargas, H.H.; Fernandez, L.A.; Parrillas, V. and Ardavin, C. (2002) Characterization of a new subpopulation of mouse CD8alpha+ B220+dendritic cells endowed with type 1 interferon production capacity and tolerogenic potential. Blood, 100, 383-390.
31. Cerundolo, V.; Hermans, I.F. and Salio, M. (2004) Dendritic cells: a journey from laboratory to clinic. Nat. Immunol., 5, 7-10.
32. Salio, M.; Palmowski, M.J.; Atzberger, A.; Hermans, I.F. and Cerundolo, V. (2004) CpG-matured murine plasmacytoid dendritic cells are capable of in vivo priming of functional CD8 T cell responses to endogenous but not exogenous antigens. J. Exp. Med., 199, 567-579.
33. Salio, M.; Cella, M.; Vermi, W.; Facchetti, F.; Palmowski, M.J.; Smith, C.L.; Shepherd, D.; Colonna, M. and Cerundolo, V. (2003) Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur. J. Immunol., 33, 1052-1062.
34. Wilson, N.S.; El-Sukkari, D. and Villadangos, J.A. (2004) Dendritic cells constitutively present self antigens in their immature state in vivo and regulate antigen presentation by controlling the rates of MHC class II synthesis and endocytosis. Blood, 103, 2187-2195.
35. Lutz, M.B. and Schuler, G. (2002) Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol., 23, 445-449.
36. Steinbrink, K.; Wolfl, M.; Jonuleit, H.; Knop, J. and Enk, A.H. (1997) Induction of tolerance by IL-10-treated dendritic cells. J. Immunol., 159, 4772-4780.
37. Hawiger, D.; Inaba, K.; Dorsett, Y.; Guo, M.; Mahnke, K.; Rivera, M.; Ravetch, J.V.; Steinman, R.M. and Nussenzweig, M.C. (2001) Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med., 194, 769-779.
38. Dhodapkar, M.V. and Steinman, R.M. (2002) Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans. Blood, 100, 174-177.
39. Dhodapkar, M.V.; Steinman, R.M.; Krasovsky, J.; Munz, C. and Bhardwaj, N. (2001) Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med., 193, 233-238.
40. Beyer, T.; Herrmann, M.; Reiser, C.; Bertling, W. and Hess, J. (2001) Bacterial carriers and virus-like-particles as antigen delivery devices: role of dendritic cells in antigen presentation. Curr. Drug Targets Infect. Disord., 1, 287-302.
41. Rescigno, M.; Granucci, F. and Ricciardi-Castagnoli, P. (2000) Molecular events of bacterial-induced maturation of dendritic cells. J. Clin. Immunol., 20, 161-166.
42. Jonuleit, H.; Kuhn, U.; Muller, G.; Steinbrink, K.; Paragnik, L.; Schmitt, E.; Knop, J. and Enk, A.H. (1997) Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol., 27, 3135-3142.
43. Mackey, M.F.; Gunn, J.R.; Maliszewsky, C.; Kikutani, H.; Noelle, R.J. and Barth, R.J. Jr. (1998) Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J. Immunol., 161,2094- 2098.
44. Mackey, M.F.; Barth, R.J. Jr. and Noelle, R.J. (1998) The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells. J. Leukoc. Biol., 63, 418-428.
45. Caux, C.; Massacrier, C.; Vanbervliet, B.; Dubois, B.; Van Kooten, C.; Durand, I. and Banchereau, J. (1994) Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med., 180, 1263-1272.
46. Aiba, S. and Tagami, H. (1999) Dendritic cells play a crucial role in innate immunity to simple chemicals. J. Invest. Dermatol. Symp. Proc., 4, 158-163.
47. Aiba, S. and Tagami, H. (1998) Dendritic cell activation induced by various stimuli, e.g. exposure to microorganisms, their products, cytokines, and simple chemicals as well as adhesion to extracellular matrix. J. Dermatol. Sci., 20, 1-13.
48. Aiba, S.; Terunuma, A.; Manome, H. and Tagami, H. (1997) Dendritic cells differently respond to haptens and irritants by their production of cytokines and expression of co-stimulatory molecules. Eur. J. Immunol., 27, 3031-3038.
49. Forster, R.; Davalos-Misslitz, A.C. and Rot, A. (2008) CCR7 and its ligands: balancing immunity and tolerance. Nat. Rev. Immunol., 8, 362-371.
50. Verhasselt, V.; Vosters, O.; Beuneu, C.; Nicaise, C.; Stordeur, P. and Goldman, M. (2004) Induction of FOXP3-expressing regulatory CD4pos T cells by human mature autologous dendritic cells. Eur. J. Immunol., 34, 762-772.
51. Vieira, P.L.; de Jong, E.C.; Wierenga, E.A.; Kapsenberg, M.L. and Kalinski, P. (2000) Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J. Immunol., 164, 4507-4512.
52. Walker, L.S. and Abbas, A.K. (2002) The enemy within: keeping self-reactive T cells at bay in the periphery. Nat. Rev. Immunol., 2, 11-19.
53. Zitvogel, L.; Tesniere, A. and Kroemer, G. (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol., 6, 715-727.
54. Emens, L.A. (2003) A new twist on autologous cancer vaccines. Cancer Biol. Ther., 2, 161-163.
55. Lizee, G.; Radvanyi, L.G.; Overwijk, W.W. and Hwu, P. (2006) Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin. Cancer Res., 12, 4794-4803.
56. Iwasaki, A. and Medzhitov, R. (2004) Toll-like receptor control of the adaptive immune responses. Nat. Immunol., 5, 987-995.
57. Pasare, C. and Medzhitov, R. (2005) Toll-like receptors: linking innate and adaptive immunity. Adv. Exp. Med. Biol., 560, 11-18.
58. Rakoff-Nahoum, S. and Medzhitov, R. (2009) Toll-like receptors and cancer. Nat. Rev. Cancer, 9, 57-63.
59. West, M.A.; Wallin, R.P.; Matthews, S.P.; Svensson, H.G.; Zaru, R.; Ljunggren, H.G.; Prescott, A.R. and Watts, C. (2004) Enhanced dendritic cell antigen capture via toll-like receptor-induced actin remodeling. Science, 305, 1153-1157.
60. Yates, R.M. and Russell, D.G. (2005) Phagosome maturation proceeds independently of stimulation of toll-like receptors 2 and 4. Immunity, 23, 409-417.
61. Blander, J.M. and Medzhitov, R. (2006) Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature, 440, 808-812.
62. Blander, J.M. and Medzhitov, R. (2004) Regulation of phagosome maturation by signals from toll-like receptors. Science, 304, 1014-1018.
63. Pasare, C. and Medzhitov, R. (2004) Toll-dependent control mechanisms of CD4 T cell activation. Immunity, 21, 733-741.
64. Yang, Y.; Huang, C.T.; Huang, X. and Pardoll, D.M. (2004) Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat. Immunol., 5, 508-515.
65. Lang, K.S.; Recher, M.; Junt, T.; Navarini, A.A.; Harris, N.L.; Freigang, S.; Odermatt, B.; Conrad, C.; Ittner, L.M.; Bauer, S.; Luther, S.A.; Uematsu, S.; Akira, S.; Hengartner, H. and Zinkernagel, R.M. (2005) Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat. Med., 11, 138-145.
66. Van Meirvenne, S.; Dullaers, M.; Heirman, C.; Straetman, L.; Michiels, A. and Thielemans, K. (2005) In vivo depletion of CD4+CD25+ regulatory T cells enhances the antigen-specific primary and memory CTL response elicited by mature mRNAelectroporated dendritic cells. Mol. Ther., 12, 922-932.
67. Shimizu, J.; Yamazaki, S. and Sakaguchi, S. (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol., 163, 5211-5218.
68. Napolitani, G.; Rinaldi, A.; Bertoni, F.; Sallusto, F. and Lanzavecchia, A. (2005) Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol., 6, 769-776.
69. Gautier, G.; Humbert, M.; Deauvieau, F.; Scuiller, M.; Hiscott, J.; Bates, E.E.; Trinchieri, G.; Caux, C. and Garrone, P. (2005) A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J. Exp. Med., 201, 1435-1446.
70. Warger, T.; Osterloh, P.; Rechtsteiner, G.; Fassbender, M.; Heib, V.; Schmid, B.; Schmitt, E.; Schild, H. and Radsak, M.P. (2006) Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood, 108, 544-550.
71. Boonstra, A.; Rajsbaum, R.; Holman, M.; Marques, R.; Asselin-Paturel, C.; Pereira, J.P.; Bates, E.E.; Akira, S.; Vieira, P.; Liu, Y.J.; Trinchieri, G. and O'Garra, A. (2006) Macrophages and myeloid dendritic cells, but not plasmacytoid dendritic cells, produce IL-10 in response to MyD88- and TRIF-dependent TLR signals, and TLR-independent signals. J. Immunol., 177, 7551-7558.
72. Kawai, T. and Akira, S. (2008) Toll-like receptor and RIG-I-like receptor signaling. Ann. N.Y. Acad. Sci., 1143, 1-20.
73. Rescigno, M.; Martino, M.; Sutherland, C.L.; Gold, M.R. and Ricciardi-Castagnoli, P. (1998) Dendritic cell survival and maturation are regulated by different signaling pathways. J. Exp. Med., 188, 2175-2180.
74. Sato, K.; Nagayama, H.; Tadokoro, K.; Juji, T. and Takahashi, T.A. (1999) Extracellular signal-regulated kinase, stress-activated protein kinase/c-Jun N-terminal kinase, and p38mapk are involved in IL-10-mediated selective repression of TNF-alpha-induced activation and maturation of human peripheral blood monocytederived dendritic cells. J. Immunol., 162, 3865-3872.
75. Re, F. and Strominger, J.L. (2001) Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J. Biol. Chem., 276, 37692-37699.
76. Caparros, E.; Munoz, P.; Sierra-Filardi, E.; Serrano-Gomez, D.; Puig-Kroger, A.; Rodriguez-Fernandez, J.L.; Mellado, M.; Sancho, J.; Zubiaur, M. and Corbi, A.L. (2006) DC-SIGN ligation on dendritic cells results in ERK and PI3K activation and modulates cytokine production. Blood, 107, 3950-3958.
77. Hirata, N.; Yanagawa, Y.; Ebihara, T.; Seya, T.; Uematsu, S.; Akira, S.; Hayashi, F.; Iwabuchi, K. and Onoe, K. (2008) Selective synergy in anti-inflammatory cytokine production upon cooperated signaling via TLR4 and TLR2 in murine conventional dendritic cells. Mol. Immunol., 45, 2734-2742.
78. Trompezinski, S.; Migdal, C.; Tailhardat, M.; Le Varlet, B.; Courtellemont, P.; Haftek, M. and Serres, M. (2008) Characterization of early events involved in human dendritic cell maturation induced by sensitizers: cross talk between MAPK signalling pathways. Toxicol. Appl. Pharmacol., 230, 397-406.
79. Luft, T.; Maraskovsky, E.; Schnurr, M.; Knebel, K.; Kirsch, M.; Gorner, M.; Skoda, R.; Ho, A.D.; Nawroth, P. and Bierhaus, A. (2004) Tuning the volume of the immune response: strength and persistence of stimulation determine migration and cytokine secretion of dendritic cells. Blood, 104, 1066-1074.
80. Luft, T.; Rodionova, E.; Maraskovsky, E.; Kirsch, M.; Hess, M.; Buchholtz, C.; Goerner, M.; Schnurr, M.; Skoda, R. and Ho, A.D. (2006) Adaptive functional differentiation of dendritic cells: integrating the network of extra- and intracellular signals. Blood, 107, 4763-4769.
81. Larange, A.; Antonios, D.; Pallardy, M. and Kerdine-Romer, S. (2009) TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation. J. Leukoc. Biol., 85, 673-683.
82. Ardeshna, K.M.; Pizzey, A.R.; Devereux, S. and Khwaja, A. (2000) The PI3 kinase, p38 SAP kinase, and NF-kappaB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells. Blood, 96, 1039-1046.
83. Boulton, T.G.; Nye, S.H.; Robbins, D.J.; Ip, N.Y.; Radziejewska, E.; Morgenbesser, S.D.; DePinho, R.A.; Panayotatos, N.; Cobb, M.H. and Yancopoulos, G. D. (1991) ERKs: a family of proteinserine/ threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell, 65, 663-675.
84. Boulton, T.G. and Cobb, M.H. (1991) Identification of multiple extracellular signal-regulated kinases (ERKs) with antipeptide antibodies. Cell Regul., 2, 357-371.
85. Derijard, B.; Hibi, M.; Wu, I.H.; Barrett, T.; Su, B.; Deng, T.; Karin, M. and Davis, R.J. (1994) JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell, 76, 1025-1037.
86. Kyriakis, J.M.; Banerjee, P.; Nikolakaki, E.; Dai, T.; Rubie, E.A.; Ahmad, M.F.; Avruch, J. and Woodgett, J.R. (1994) The stressactivated protein kinase subfamily of c-Jun kinases. Nature, 369, 156-160.
87. Lee, J.C.; Laydon, J.T.; McDonnell, P.C.; Gallagher, T.F.; Kumar, S.; Green, D.; McNulty, D.; Blumenthal, M.J.; Heys, J.R.; Landvatter, S.W.; Strickler, J.E.; McLaughlin M.M.; Siemens, I.R.; Fisher, S.M.; Livi, G.P.; White, J.R.; Adams, J.L. and Young, P.R. (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature, 372, 739-746.
88. Han, J.; Lee, J.D.; Bibbs, L., and Ulevitch, R.J. (1994) A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science, 265, 808-811.
89. Zhang, J.; Yang, P.L. and Gray, N.S. (2009) Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer, 9, 28-39.
90. Beutler, B.A. (2009) TLRs and innate immunity. Blood, 113, 1399-1407.
91. Hacker, H.; Redecke, V.; Blagoev, B.; Kratchmarova, I.; Hsu, L.C.; Wang, G.G.; Kamps, M.P.; Raz, E.; Wagner, H.; Hacker, G.; Mann, M. and Karin, M. (2006) Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature, 439, 204-207.
92. Sato, S.; Sanjo, H.; Takeda, K.; Ninomiya-Tsuji, J.; Yamamoto, M.; Kawai, T.; Matsumoto, K.; Takeuchi, O. and Akira, S. (2005) Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat. Immunol., 6, 1087-1095.
93. Yamamoto, M.; Okamoto, T.; Takeda, K.; Sato, S.; Sanjo, H.; Uematsu, S.; Saitoh, T.; Yamamoto, N.; Sakurai, H.; Ishii, K.J.; Yamaoka, S.; Kawai, T.; Matsuura, Y.; Takeuchi, O. and Akira, S. (2006) Key function for the Ubc13 E2 ubiquitin-conjugating enzyme in immune receptor signaling. Nat. Immunol., 7, 962-970.
94. Pearson, G.; Robinson, F.; Beers Gibson, T.; Xu, B.E.; Karandikar, M.; Berman, K. and Cobb, M.H. (2001) Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev. 22, 153-183.
95. Nakayama, K.; Ota, Y.; Okugawa, S.; Ise, N.; Kitazawa, T.; Tsukada, K.; Kawada, M.; Yanagimoto, S. and Kimura, S. (2003) Raf1 plays a pivotal role in lipopolysaccharide-induced activation of dendritic cells. Biochem. Biophys. Res. Commun., 308, 353-360.
96. Zimmermann, S.; Rommel, C.; Ziogas, A.; Lovric, J.; Moelling, K. and Radziwill, G. (1997) MEK1 mediates a positive feedback on Raf-1 activity independently of Ras and Src. Oncogene, 15, 1503-1511.
97. Wang, C.; Deng, L.; Hong, M.; Akkaraju, G.R.; Inoue, J. and Chen, Z.J. (2001) TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature, 412, 346-351.
98. Junttila, M.R.; Li, S.P. and Westermarck, J. (2008) Phosphatasemediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J., 22, 954-965.
99. Agrawal, A.; Dillon, S.; Denning, T.L. and Pulendran, B. (2006) ERK1-/- mice exhibit Th1 cell polarization and increased susceptibility to experimental autoimmune encephalomyelitis. J. Immunol., 176, 5788-5796.
100. Escors, D.; Lopes, L.; Lin, R.; Hiscott, J.; Akira, S.; Davis, R.J. and Collins, M.K. (2008) Targeting dendritic cell signaling to regulate the response to immunization. Blood, 111, 3050-3061.
101. Puig-Kroger, A.; Relloso, M.; Fernandez-Capetillo, O.; Zubiaga, A.; Silva, A.; Bernabeu, C. and Corbi, A.L. (2001) Extracellular signal-regulated protein kinase signaling pathway negatively regulates the phenotypic and functional maturation of monocytederived human dendritic cells. Blood, 98, 2175-2182.
102. Yanagawa, Y. and Onoe, K. (2007) Enhanced IL-10 production by TLR4- and TLR2-primed dendritic cells upon TLR restimulation. J. Immunol., 178, 6173-6180.
103. Slack, E.C.; Robinson, M.J.; Hernanz-Falcon, P.; Brown, G.D.; Williams, D.L.; Schweighoffer, E.; Tybulewicz, V.L. and Reis e Sousa, C. (2007) Syk-dependent ERK activation regulates IL-2 and IL-10 production by DC stimulated with zymosan. Eur. J.Immunol., 37, 1600-1612.
104. Qian, C.; Jiang, X.; An, H.; Yu, Y.; Guo, Z.; Liu, S.; Xu, H. and Cao, X. (2006) TLR agonists promote ERK-mediated preferential IL-10 production of regulatory dendritic cells (diffDCs), leading to NK-cell activation. Blood, 108, 2307-2315.
105. Manicassamy, S.; Ravindran, R.; Deng, J.; Oluoch, H.; Denning, T.L.; Kasturi, S.P.; Rosenthal, K.M.; Evavold, B.D. and Pulendran, B. (2009) Toll-like receptor 2-dependent induction of vitamin A-metabolizing enzymes in dendritic cells promotes T regulatory responses and inhibits autoimmunity. Nat. Med., 15, 401-409.
106. Ehlers, M. and Ravetch, J.V. (2007) Opposing effects of Toll-like receptor stimulation induce autoimmunity or tolerance. Trends Immunol., 28, 74-79.
107. Conroy, H.; Marshall, N.A. and Mills, K.H. (2008) TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene 27, 168-180.
108. Jackson, A.M.; Mulcahy, L.A.; Zhu, X.W.; O'Donnell, D. and Patel, P.M. (2008) Tumour-mediated disruption of dendritic cell function: inhibiting the MEK1/2-p44/42 axis restores IL-12 production and Th1-generation. Int. J. Cancer, 123, 623-632.
109. Fujita, H.; Asahina, A.; Komine, M. and Tamaki, K. (2007) ERK inhibitor PD98059 promotes the phenotypic and functional maturation of murine resident Langerhans cells. J. Dermatol., 34, 403-406.
110. Yanagawa, Y.; Iijima, N.; Iwabuchi, K. and Onoe, K. (2002) Activation of extracellular signal-related kinase by TNF-alpha controls the maturation and function of murine dendritic cells. J. Leukoc. Biol., 71, 125-132.
111. Roberts, P.J. and Der, C.J. (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene, 26, 3291-3310.
112. Ozao-Choy, J.; Ma, G.; Kao, J.; Wang, G.X.; Meseck, M.; Sung, M.; Schwartz, M.; Divino, C.M.; Pan, P.Y. and Chen, S.H. (2009) The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res., 69, 2514-2522.
113. Xin, H.; Zhang, C.; Herrmann, A.; Du, Y.; Figlin, R. and Yu, H. (2009) Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res., 69, 2506-2513.
114. Ninomiya-Tsuji, J.; Kishimoto, K.; Hiyama, A.; Inoue, J.; Cao, Z. and Matsumoto, K. (1999) The kinase TAK1 can activate the NIKI kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature, 398, 252-256.
115. Moriguchi, T.; Kuroyanagi, N.; Yamaguchi, K.; Gotoh, Y.; Irie, K.; Kano, T.; Shirakabe, K.; Muro, Y.; Shibuya, H.; Matsumoto, K.; Nishida, E. and Hagiwara, M. (1996) A novel kinase cascade mediated by mitogen-activated protein kinase kinase 6 and MKK3. J. Biol. Chem., 271, 13675-13679.
116. Zarubin, T. and Han, J. (2005) Activation and signaling of the p38 MAP kinase pathway. Cell Res., 15, 11-18.
117. Arrighi, J.F.; Rebsamen, M.; Rousset, F.; Kindler, V. and Hauser, C. (2001) A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-alpha, and contact sensitizers. J. Immunol., 166, 3837-3845.
118. Yu, Q.; Kovacs, C.; Yue, F.Y. and Ostrowski, M.A. (2004) The role of the p38 mitogen-activated protein kinase, extracellular signal-regulated kinase, and phosphoinositide-3-OH kinase signal transduction pathways in CD40 ligand-induced dendritic cell activation and expansion of virus-specific CD8+ T cell memory responses. J. Immunol., 172, 6047-6056.
119. Lu, H.T.; Yang, D.D.; Wysk, M.; Gatti, E.; Mellman, I.; Davis, R.J. and Flavell, R.A. (1999) Defective IL-12 production in mitogenactivated protein (MAP) kinase kinase 3 (Mkk3)-deficient mice. EMBO J., 18, 1845-1857.
120. Morton, S.; Davis, R.J. and Cohen, P. (2004) Signalling pathways involved in multisite phosphorylation of the transcription factor ATF-2. FEBS Lett., 572, 177-183.
121. Saccani, S.; Pantano, S. and Natoli, G. (2002). p38-Dependent marking of inflammatory genes for increased NF-kappa B recruitment. Nat. Immunol., 3, 69-75.
122. Xiao, Y.Q.; Malcolm, K.; Worthen, G.S.; Gardai, S.; Schiemann, W.P.; Fadok, V.A.; Bratton, D.L. and Henson, P.M. (2002) Crosstalk between ERK and p38 MAPK mediates selective suppression of pro-inflammatory cytokines by transforming growth factor-beta. J. Biol. Chem., 277, 14884-14893.
123. Li, S.P.; Junttila, M.R.; Han, J.; Kahari, V.M. and Westermarck, J. (2003) p38 Mitogen-activated protein kinase pathway suppresses cell survival by inducing dephosphorylation of mitogen-activated protein/extracellular signal-regulated kinase kinase 1,2. Cancer Res., 63, 3473-3477.
124. Zhang, B.; Xia, H.Q.; Cleghorn, G.; Gobe, G.; West, M. and Wei, M.Q. (2001) A highly efficient and consistent method for harvesting large volumes of high-titre lentiviral vectors. Gene Ther., 8, 1745-1751.
125. Gupta, S.; Barrett, T.; Whitmarsh, A.J.; Cavanagh, J.; Sluss, H.K.; Derijard, B. and Davis, R.J. (1996) Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J., 15, 2760-2770.
126. Morton, S.; Davis, R.J.; McLaren, A. and Cohen, P. (2003) A reinvestigation of the multisite phosphorylation of the transcription factor c-Jun. EMBO J., 22, 3876-3886.
127. Hammaker, D.R.; Boyle, D.L.; Inoue, T. and Firestein, G.S. (2007) Regulation of the JNK pathway by TGF-beta activated kinase 1 in rheumatoid arthritis synoviocytes. Arthritis Res. Ther., 9, R57.
128. Nakahara, T.; Uchi, H.; Urabe, K.; Chen, Q.; Furue, M. and Moroi, Y. (2004) Role of c-Jun N-terminal kinase on lipopolysaccharide induced maturation of human monocyte-derived dendritic cells. Int. Immunol., 16, 1701-1709.
129. Sen, R. and Baltimore, D. (1986) Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell, 47, 921-928.
130. Ghosh, S. and Karin, M. (2002) Missing pieces in the NF-kappaB puzzle. Cell, 109, S81-S96.
131. Weih, D.S.; Yilmaz, Z.B. and Weih, F. (2001) Essential role of RelB in germinal center and marginal zone formation and proper expression of homing chemokines. J. Immunol., 167, 1909-1919.
132. Weih, F.; Carrasco, D.; Durham, S.K.; Barton, D.S.; Rizzo, C.A.; Ryseck, R.P.; Lira, S.A. and Bravo, R. (1995) Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family. Cell, 80, 331-340.
133. Caamano, J.H.; Rizzo, C.A.; Durham, S.K.; Barton, D.S.; Raventos-Suarez, C.; Snapper, C. M. and Bravo, R. (1998) Nuclear factor (NF)-kappa B2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responses. J. Exp. Med., 187, 185-196.
134. Franzoso, G.; Carlson, L.; Poljak, L.; Shores, E.W.; Epstein, S.; Leonardi, A.; Grinberg, A.; Tran, T.; Scharton-Kersten, T.; Anver, M.; Love, P.; Brown, K. and Siebenlist, U. (1998) Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. J. Exp. Med., 187, 147-159.
135. Carrasco, D.; Cheng, J.; Lewin, A.; Warr, G.; Yang, H.; Rizzo, C.; Rosas, F.; Snapper, C. and Bravo, R. (1998) Multiple hemopoietic defects and lymphoid hyperplasia in mice lacking the transcriptional activation domain of the c-Rel protein. J. Exp. Med., 187, 973-984.
136. Poljak, L.; Carlson, L.; Cunningham, K.; Kosco-Vilbois, M.H. and Siebenlist, U. (1999) Distinct activities of p52/NF-kappa B required for proper secondary lymphoid organ microarchitecture: functions enhanced by Bcl-3. J. Immunol., 163, 6581-6588.
137. Burkly, L.; Hession, C.; Ogata, L.; Reilly, C.; Marconi, L.A.; Olson, D.; Tizard, R.; Cate, R. and Lo, D. (1995) Expression of relB is required for the development of thymic medulla and dendritic cells. Nature, 373, 531-536.
138. Martin, E.; O'Sullivan, B.; Low, P. and Thomas, R. (2003) Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10. Immunity, 18, 155-167.
139. Rothwarf, D.M. and Karin, M. (1999) The NF-kappa B activation pathway: a paradigm in information transfer from membrane to nucleus. Sci. STKE, 1999, RE1.
140. Edwards, M.R.; Bartlett, N.W.; Clarke, D.; Birrell, M.; Belvisi, M. and Johnston, S.L. (2009) Targeting the NF-kappaB pathway in asthma and chronic obstructive pulmonary disease. Pharmacol. Ther., 121, 1-13.
141. Wang, R.F.; Miyahara, Y. and Wang, H.Y. (2008) Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene, 27, 181-189.
142. Lee, C.H.; Jeon, Y.T.; Kim, S.H. and Song, Y.S. (2007) NFkappaB as a potential molecular target for cancer therapy. Biofactors, 29, 19-35.
143. Akira, S.; Uematsu, S. and Takeuchi, O. (2006) Pathogen recognition and innate immunity. Cell, 124, 783-801.
144. Scheidereit, C. (1998) Signal transduction. Docking IkappaB kinases. Nature, 395, 225-226.
145. Courtois, G.; Smahi, A. and Israel, A. (2001) NEMO/IKK gamma: linking NF-kappa B to human disease. Trends Mol. Med., 7, 427-430.
146. Karin, M. (1999) How NF-kappaB is activated? the role of the IkappaB kinase (IKK) complex. Oncogene, 18, 6867-6874.
147. Dawson, S.; Hastings, R.; Takayanagi, K.; Reynolds, S.; Low, P.; Billett, M. and Mayer, R.J. (1997) The 26S-proteasome: regulation and substrate recognition. Mol. Biol. Rep., 24, 39-44.
148. Hu, M.C.; Wang, Y.; Qiu, W.R.; Mikhail, A. Meyer, C.F. and Tan, T.H. (1999) Hematopoietic progenitor kinase-1 (HPK1) stress response signaling pathway activates IkappaB kinases (IKKalpha/ beta) and IKK-beta is a developmentally regulated protein kinase. Oncogene, 18, 5514-5524.
149. Li, Q.; Van Antwerp, D.; Mercurio, F.; Lee, K.F. and Verma, I.M. (1999) Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science, 284, 321-325.
150. Takeda, K.; Takeuchi, O.; Tsujimura, T.; Itami, S.; Adachi, O.; Kawai, T.; Sanjo, H.; Yoshikawa, K.; Terada, N. and Akira, S. (1999) Limb and skin abnormalities in mice lacking IKKalpha. Science, 284, 313-316.
151. Li, Z.W.; Chu, W.; Hu, Y.; Delhase, M.; Deerinck, T.; Ellisman, M.; Johnson, R. and Karin, M. (1999) The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J. Exp. Med., 189, 1839-1845.
152. Hacker, H. and Karin, M. (2006) Regulation and function of IKK and IKK-related kinases. Sci. STKE, re13.
153. Dejardin, E.; Droin, N.M.; Delhase, M.; Haas, E.; Cao, Y.; Makris, C.; Li, Z.W.; Karin, M.; Ware, C.F. and Green, D.R. (2002) The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity, 17, 525-535.
154. Novack, D.V.; Yin, L.; Hagen-Stapleton, A.; Schreiber, R.D.; Goeddel, D.V.; Ross, F.P. and Teitelbaum, S.L. (2003) The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis. J. Exp. Med., 198, 771-781.
155. Senftleben, U.; Cao, Y.; Xiao, G.; Greten, F.R.; Krahn, G.; Bonizzi, G.; Chen, Y.; Hu, Y.; Fong, A.; Sun, S.C. and Karin, M. (2001) Activation by IKKalpha of a second, evolutionary conserved, NFkappa B signaling pathway. Science, 293, 1495-1499.
156. Lawrence, T. and Bebien, M. (2007) IKKalpha in the regulation of inflammation and adaptive immunity. Biochem. Soc. Trans., 35, 270-272.
157. Naumann, M. and Scheidereit, C. (1994) Activation of NF-kappa B in vivo is regulated by multiple phosphorylations. EMBO J., 13, 4597-4607.
158. Ito, K.; Charron, C.E. and Adcock, I.M. (2007) Impact of protein acetylation in inflammatory lung diseases. Pharmacol. Ther., 116, 249-265.
159. Chen, L.F.; Mu, Y. and Greene, W.C. (2002) Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J., 21, 6539-6548.
160. Chen, L.F.; Williams, S.A.; Mu, Y.; Nakano, H.; Duerr, J.M.; Buckbinder, L. and Greene, W.C. (2005) NF-kappaB RelA phosphorylation regulates RelA acetylation. Mol. Cell Biol., 25, 7966-7975.
161. Breckpot, K.; Aerts-Toegaert, C.; Heirman, C.; Peeters, U.; Beyaert, R.; Aerts, J.L. and Thielemans, K. (2009) Attenuated expression of A20 markedly increases the efficacy of doublestranded RNA-activated dendritic cells as an anti-cancer vaccine. J. Immunol., 182, 860-870.
162. Kawai, T. and Akira, S. (2007) Signaling to NF-kappaB by Tolllike receptors. Trends Mol. Med., 13, 460-469.
163. Coornaert, B.; Carpentier, I. and Beyaert, R. (2009) A20: central gatekeeper in inflammation and immunity. J. Biol. Chem., 284,8217-8221.
164. Shi, M.; Deng, W.; Bi, E.; Mao, K.; Ji, Y.; Lin, G.; Wu, X.; Tao, Z.; Li, Z.; Cai, X.; Sun, S.; Xiang, C. and Sun, B. (2008) TRIM30 alpha negatively regulates TLR-mediated NF-kappa B activation by targeting TAB2 and TAB3 for degradation. Nat. Immunol., 9, 369-377.
165. Bowie, A.G. (2008) TRIM-ing down Tolls. Nat. Immunol., 9, 348-350.
166. Barisic, S.; Strozyk, E.; Peters, N.; Walczak, H. and Kulms, D. (2008) Identification of PP2A as a crucial regulator of the NFkappaB feedback loop: its inhibition by UVB turns NF-kappaB into a pro-apoptotic factor. Cell Death Differ., 15, 1681-1690.
167. Dixit, V.M.; Green, S.; Sarma, V.; Holzman, L.B.; Wolf, F.W.; O'Rourke, K.; Ward, P.A.; Prochownik, E.V and Marks, R.M. (1990) Tumor necrosis factor-alpha induction of novel gene products in human endothelial cells including a macrophagespecific chemotaxin. J. Biol. Chem., 265, 2973-2978.
168. Song, X.T.; Evel-Kabler, K.; Shen, L.; Rollins, L.; Huang, X.F. and Chen, S.Y. (2008) A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat. Med., 14, 258-265.
169. Beyaert, R.; Heyninck, K. and Van Huffel, S. (2000) A20 and A20-binding proteins as cellular inhibitors of nuclear factor-kappa Bdependent gene expression and apoptosis. Biochem. Pharmacol., 60, 1143-1151.
170. Wertz, I.E.; O'Rourke, K.M.; Zhou, H.; Eby, M.; Aravind, L.; Seshagiri, S.; Wu, P.; Wiesmann, C.; Baker, R.; Boone, D.L.; Ma, A.; Koonin, E.V. and Dixit, V.M. (2004) De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature, 430, 694-699.
171. Evans, P.C.; Ovaa, H.; Hamon, M.; Kilshaw, P.J.; Hamm, S.; Bauer, S.; Ploegh, H.L. and Smith, T.S. (2004) Zinc-finger protein A20, a regulator of inflammation and cell survival, has deubiquitinating activity. Biochem. J., 378, 727-734.
172. Boone, D.L.; Turer, E.E.; Lee, EG.; Ahmad, R.C.; Wheeler, M.T.; Tsui, C.; Hurley, P.; Chien, M.; Chai, S.; Hitotsumatsu, O.; McNally, E.; Pickart, C. and Ma, A. (2004) The ubiquitinmodifying enzyme A20 is required for termination of Toll-like receptor responses. Nat. Immunol., 5, 1052-1060.
173. Heyninck, K. and Beyaert, R. (2005) A20 inhibits NF-kappaB activation by dual ubiquitin-editing functions. Trends Biochem. Sci., 30, 1-4.
174. Zhang, S.Q.; Kovalenko, A.; Cantarella, G. and Wallach, D. (2000) Recruitment of the IKK signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKKgamma) upon receptor stimulation. Immunity, 12, 301-311.
175. Saitoh, T.; Yamamoto, M.; Miyagishi, M.; Taira, K.; Nakanishi, M.; Fujita, T.; Akira, S.; Yamamoto, N. and Yamaoka, S. (2005) A20 is a negative regulator of IFN regulatory factor 3 signaling. J. Immunol., 174, 1507-1512.
176. Wang, Y.Y.; Li, L.; Han, K.J.; Zhai, Z. and Shu, H.B. (2004) A20 is a potent inhibitor of TLR3- and Sendai virus-induced activation of NF-kappaB and ISRE and IFN-beta promoter. FEBS Lett., 576, 86-90.
177. Heyninck, K. and Beyaert, R. (1999) The cytokine-inducible zinc finger protein A20 inhibits IL-1-induced NF-kappaB activation at the level of TRAF6. FEBS Lett., 442, 147-150.
178. Hutti, J.E.; Turk, B.E.; Asara, J.M.; Ma, A.; Cantley, L.C. and Abbott, D.W. (2007) IkappaB kinase beta phosphorylates the K63 deubiquitinase A20 to cause feedback inhibition of the NF-kappaB pathway. Mol. Cell Biol., 27, 7451-7461.
179. Breckpot, K.; Dullaers, M.; Bonehill, A.; van Meirvenne, S.; Heirman, C.; de Greef, C.; van der Bruggen, P. and Thielemans, K. (2003) Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J. Gene Med., 5, 654-667.
180. Bonehill, A.; Heirman, C.; Tuyaerts, S.; Michiels, A.; Breckpot, K.; Brasseur, F.; Zhang, Y.; Van Der Bruggen, P. and Thielemans, K. (2004) Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J. Immunol., 172, 6649-6657.
181. Breckpot, K.; Emeagi, P.U. and Thielemans, K. (2008) Lentiviral vectors for anti-tumor immunotherapy. Curr. Gene Ther., 8, 438-448.
182. Breckpot, K.; Aerts, J.L. and Thielemans, K. (2007) Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Ther., 14, 847-862.
183. Ribas, A. (2005) Genetically modified dendritic cells for cancer immunotherapy. Curr. Gene Ther., 5, 619-628.
184. Van Tendeloo, V.F.; Ponsaerts, P. and Berneman, Z.N. (2007) mRNA-based gene transfer as a tool for gene and cell therapy. Curr. Opin. Mol. Ther., 9, 423-431.
185. da Silva Correia, J.; Soldau, K.; Christen, U.; Tobias, P.S. and Ulevitch, R.J. (2001) Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex. Transfer from CD14 to TLR4 and MD-2. J. Biol. Chem., 276, 21129-21135.
186. Pasare, C. and Medzhitov, R. (2003) Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science, 299, 1033-1036.
187. Abdel-Wahab, Z.; Cisco, R.; Dannull, J.; Ueno, T.; Abdel-Wahab, O.; Kalady, M.F.; Onaitis, M.W.; Tyler, D.S. and Pruitt, S.K. (2005) Cotransfection of DC with TLR4 and MART-1 RNA induces MART-1-specific responses. J. Surg. Res., 124, 264-273.
188. Bonehill, A.; Tuyaerts, S.; Van Nuffel, A.M.; Heirman, C.; Bos, T.J.; Fostier, K.; Neyns, B. and Thielemans, K. (2008) Enhancing the T-cell stimulatory capacity of human dendritic cells by coelectroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol. Ther., 16, 1170-1180.
189. Cisco, R.M.; Abdel-Wahab, Z.; Dannull, J.; Nair, S.; Tyler, D.S.; Gilboa, E.; Vieweg, J.; Daaka, Y. and Pruitt, S.K. (2004) Induction of human dendritic cell maturation using transfection with RNA encoding a dominant positive toll-like receptor 4. J. Immunol., 172, 7162-7168.
190. Xu, Y.; Darcy, P.K. and Kershaw, M.H. (2007) Tumor-specific dendritic cells generated by genetic redirection of Toll-like receptor signaling against the tumor-associated antigen, erbB2. Cancer Gene Ther., 14, 773-780.
191. Hamdy, S.; Molavi, O.; Ma, Z.; Haddadi, A.; Alshamsan, A.; Gobti, Z.; Elhasi, S.; Samuel, J. and Lavasanifar, A. (2008) Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cellmediated anti-tumor immunity. Vaccine, 26, 5046-5057.
192. Tan, P.H.; Beutelspacher, S.C.; Xue, S.A.; Wang, Y.H.; Mitchell, P.; McAlister, J.C.; Larkin, D.F.; McClure, M.O.; Stauss, H.J.; Ritter, M.A.; Lombardi, G. and George, A.J. (2005) Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood, 105, 3824-3832.
193. Breckpot, K.; Emeagi, P.; Dullaers, M.; Michiels, A.; Heirman, C. and Thielemans, K. (2007) Activation of immature monocytederived dendritic cells after transduction with high doses of lentiviral vectors. Hum. Gene Ther., 18, 536-546.
194. Brown, B.D.; Sitia, G.; Annoni, A.; Hauben, E.; Sergi, L.S.; Zingale, A.; Roncarolo, M.G.; Guidotti, L.G. and Naldini, L. (2007) In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance. Blood, 109, 2797-2805.
195. Beignon, A.S.; McKenna, K.; Skoberne, M.; Manches, O.; DaSilva, I.; Kavanagh, D.G.; Larsson, M.; Gorelick, R.J.; Lifson, J.D. and Bhardwaj, N. (2005) Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J. Clin. Invest., 115, 3265-3275.
196. Fonteneau, J.F.; Larsson, M.; Beignon, A.S.; McKenna, K.; Dasilva, I.; Amara, A.; Liu, Y.J.; Lifson, J.D.; Littman, D.R. and Bhardwaj, N. (2004) Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. J. Virol., 78, 5223-5232.
197. Pichlmair, A.; Diebold, S.S.; Gschmeissner, S.; Takeuchi, Y.; Ikeda, Y.; Collins, M.K. and Reis e Sousa, C. (2007) Tubulovesicular structures within vesicular stomatitis virus G protein-pseudotyped lentiviral vector preparations carry DNA and stimulate antiviral responses via Toll-like receptor 9. J. Virol., 81, 539-547.
198. He, Y.; Zhang, J.; Donahue, C. and Falo, L.D. Jr. (2006) Skinderived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity, 24, 643-656.
199. Esslinger, C.; Chapatte, L.; Finke, D.; Miconnet, I.; Guillaume, P.; Levy, F. and MacDonald, H. R. (2003) In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. J. Clin. Invest., 111, 1673-1681.
200. Dullaers, M.; Van Meirvenne, S.; Heirman, C.; Straetman, L.; Bonehill, A.; Aerts, J.L.; Thielemans, K. and Breckpot, K. (2006) Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther., 13, 630-640.
201. Palmowski, M.J.; Lopes, L.; Ikeda, Y.; Salio, M.; Cerundolo, V. and Collins, M.K. (2004) Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response. J. Immunol., 172, 1582-1587.
202. Kim, J.H.; Majumder, N.; Lin, H.; Watkins, S.; Falo, L.D. Jr. and You, Z. (2005) Induction of therapeutic antitumor immunity by in vivo administration of a lentiviral vaccine. Hum. Gene Ther., 16, 1255-1266.
203. Chapatte, L.; Colombetti, S.; Cerottini, J.C. and Levy, F. (2006) Efficient induction of tumor antigen-specific CD8+ memory T cells by recombinant lentivectors. Cancer Res., 66, 1155-1160.
204. Rowe, H.M.; Lopes, L.; Ikeda, Y.; Bailey, R.; Barde, I.; Zenke, M.; Chain, B.M. and Collins, M.K. (2006) Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene. Mol. Ther., 13, 310-319.
205. Andreakos, E.; Williams, R.O.; Wales, J.; Foxwell, B.M. and Feldmann, M (2006) Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant. Proc. Natl. Acad. Sci. USA, 103, 14459-14464.
206. Akazawa, T.; Ebihara, T.; Okuno, M.; Okuda, Y.; Shingai, M.; Tsujimura, K.; Takahashi, T.; Ikawa, M.; Okabe, M.; Inoue, N.; Okamoto-Tanaka, M.; Ishizaki, H.; Miyoshi, J.; Matsumoto, M. and Seya, T. (2007) Antitumor NK activation induced by the Tolllike receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proc. Natl. Acad. Sci. USA, 104, 252-257.
207. Akazawa, T.; Shingai, M.; Sasai, M.; Ebihara, T.; Inoue, N.; Matsumoto, M. and Seya T. (2007) Tumor immunotherapy using bone marrow-derived dendritic cells overexpressing Toll-like receptor adaptors. FEBS Lett, 581, 3334-3340.
208. Rowe, H.M.; Lopes, L.; Brown, N.; Efklidou, S.; Smallie, T.; Karrar, S.; Kaye, P.M. and Collins, M.K. (2009) Expression of vFLIP in a lentiviral vaccine vector activates NF-{kappa}B, matures dendritic cells, and increases CD8+ T-cell responses. J. Virol., 83, 1555-1562.
209. Karwacz, K.; Mukherjee, S.; Apolonia, L.; Blundell, M.P.; Bouma, G.; Escors, D.; Collins, M.K. and Thrasher, A.J. (2009) Nonintegrating lentivector vaccines stimulate prolonged T-cell and antibody responses and are effective in tumor therapy. J. Virol., 83, 3094-3103.
210. Raingeaud, J.; Whitmarsh, A.J.; Barrett, T.; Derijard, B. and Davis, R.J. (1996) MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol. Cell Biol., 16, 1247-1255.
211. Kuate, S.; Wagner, R. and Uberla, K. (2002) Development and characterization of a minimal inducible packaging cell line for simian immunodeficiency virus-based lentiviral vectors. J. Gene Med., 4, 347-355.
212. Werner, S.L.; Kearns, J.D.; Zadorozhnaya, V.; Lynch, C.; O'Dea, E.; Boldin, M.P.; Ma, A.; Baltimore, D. and Hoffmann, A. (2008) Encoding NF-kappaB temporal control in response to TNF: distinct roles for the negative regulators IkappaBalpha and A20. Genes Dev., 22, 2093-2101.